MTRR Gene: B12 Recycling, Methylation, and the MTHFR Companion Variant

The Methylation Cycle: Two Arms, Two Genes

The methylation cycle (also called the one-carbon cycle or methionine cycle) is a metabolic loop that produces SAMe (S-adenosylmethionine) — the universal methyl donor used in over 200 reactions throughout the body including DNA methylation, neurotransmitter synthesis, gene regulation, creatine production, and phospholipid synthesis.

The cycle has two key enzyme steps that are commonly impaired by genetic variants:

• Step 1 — MTHFR: Converts dietary folate (or folic acid) into methylfolate (5-MTHF), the active form that can enter the cycle. MTHFR C677T and A1298C variants reduce this conversion by 30-70%.
• Step 2 — MTR + MTRR: Methionine synthase (MTR) uses methylfolate to transfer a methyl group to homocysteine, converting it to methionine and regenerating tetrahydrofolate. This reaction requires active methylcobalamin (methyl-B12) as a cofactor. Over time, the methylcobalamin becomes oxidized and inactive. MTRR (methionine synthase reductase) is the enzyme that regenerates oxidized B12 back to active methylcobalamin by transferring a methyl group from SAMe to cobalamin.

MTRR is therefore the maintenance enzyme of the entire B12-dependent arm of the methylation cycle. If MTRR is impaired, MTR gradually loses its active cofactor and slows. Homocysteine builds up. Methylfolate that can't donate its methyl group to the cycle backs up (the "methyl trap" — folate gets trapped in the methylfolate form and can't be recycled). SAMe production falls.

What MTRR A66G Does to the Enzyme

The A66G variant (rs1801394) changes amino acid 22 from isoleucine to methionine in the MTRR protein. This substitution is in the FMN-binding domain of the enzyme — the region that binds flavin mononucleotide, a cofactor required for the electron transfer reaction that regenerates cobalamin.

The biochemical consequence: the variant MTRR enzyme has reduced binding affinity for FMN and decreased electron transfer efficiency. The rate at which oxidized B12 is recycled back to active methylcobalamin is lower, meaning the MTR enzyme runs on degrading cofactor and eventually stalls.

Functionally, the GG genotype is associated with:

• Elevated homocysteine: Even with normal dietary B12 intake, homocysteine tends to be modestly higher in GG individuals. The elevation is less dramatic than in severe MTHFR deficiency alone, but compounds with it.
• Functional B12 insufficiency despite normal serum B12: Standard serum B12 testing measures total B12 (mostly inactive forms). Functional B12 activity (measured by holotranscobalamin, methylmalonic acid, or homocysteine) may be compromised even when total serum B12 appears adequate.
• Neural tube defect risk: MTRR A66G was identified as a risk factor for neural tube defects (NTDs) independent of MTHFR status in the original studies by Zhu et al. (2003). The combination of MTRR GG + MTHFR TT substantially increases NTD risk.
• Elevated methylmalonic acid (MMA): MMA accumulates when cobalamin function is impaired. Elevated urine or serum MMA with normal or borderline serum B12 is a classical sign of functional B12 deficiency — and a finding consistent with MTRR GG phenotype.

Why Cyanocobalamin Doesn't Work Here

Cyanocobalamin is the synthetic form of B12 used in most inexpensive supplements and in the vast majority of B12 fortified foods. It is not biologically active as a cofactor — it must be converted to either methylcobalamin (for the MTR reaction in the cytoplasm) or adenosylcobalamin (for mitochondrial reactions including MMA clearance).

Conversion of cyanocobalamin to methylcobalamin requires the MTRR enzyme itself. This creates a circular dependency problem for MTRR GG individuals: they need MTRR to activate the B12 that's supposed to compensate for impaired MTRR function. High-dose cyanocobalamin partially overcomes this by mass action — flooding the pathway eventually produces some methylcobalamin — but it is far less efficient than giving the active form directly.

Methylcobalamin bypasses the MTRR-dependent conversion step entirely. It is directly usable as a cofactor for MTR. For MTRR GG individuals, methylcobalamin supplementation can compensate for the reduced enzyme efficiency because the active form is supplied pre-made, and MTRR's job of regenerating it from the oxidized form is simply needed less when methylcobalamin is replenished from external supply.

Adenosylcobalamin (hydroxocobalamin can convert to both) handles the mitochondrial arm of B12 metabolism (propionate metabolism, MMA clearance). Some MTRR individuals with elevated MMA benefit from adenosylcobalamin or hydroxocobalamin in addition to methylcobalamin to address both functional requirements.

MTRR + MTHFR: The Compound Phenotype

In isolation, MTRR A66G GG has modest effects on homocysteine and methylation. The real clinical significance emerges when MTRR GG is combined with MTHFR C677T TT or A1298C CC.

The mechanism of compounding: MTHFR impairment means less methylfolate is produced to donate methyl groups through MTR. MTRR impairment means the B12 cofactor for MTR is cycling less efficiently. Both inputs to the MTR reaction are compromised simultaneously. Homocysteine elevation and SAMe depletion are substantially more severe in the combined genotype than in either alone.

A 2004 study by Doolin et al. in Genetics in Medicine found that the combination of MTHFR C677T TT + MTRR A66G GG produced homocysteine levels significantly higher than either single-gene impairment, and that correcting this combined phenotype required both methylfolate and methylcobalamin supplementation — methylcobalamin alone (without methylfolate) was insufficient, and vice versa.

Homocysteine as a Clinical Marker

For MTRR GG individuals — especially those who also carry MTHFR variants — serum homocysteine is the most actionable biomarker. It reflects the integrated output of the entire methylation cycle: when folate and B12 inputs are working, homocysteine gets cleared efficiently; when they're impaired, it accumulates.

Target ranges: Optimal homocysteine is below 7-9 µmol/L. Levels above 10 µmol/L are associated with cardiovascular risk (independent of LDL), cognitive decline, and neural tube defect risk in pregnancy. Levels above 15 µmol/L (hyperhomocysteinemia) significantly increase stroke, dementia, and Alzheimer's risk.

A 2002 meta-analysis in JAMA by Wald et al. found that each 5 µmol/L increase in homocysteine was associated with a 32% increased ischemic heart disease risk and a 59% increased stroke risk. Genetic elevation of homocysteine via MTHFR and MTRR variants falls within the causally relevant range for these outcomes — not just as a biomarker, but as a mechanism.

References